Liver transplantation poses enormous and complex medical problems. Of
the infective complications, bacterial infections are the commonest ov
erall, but the single commonest is cytomegalovirus and the most deadly
are the fungal infections. Therapeutic options and possibilities for
prophylaxis are improving. Rejection, both acute and chronic, is the o
ther major cause of mortality, and the balance between immunosuppressi
on and infection is difficult. Cyclosporin treatment contributes to re
nal impairment. hypertension, and multitudinous potential neurological
problems. The risk of long-term neoplasia is unclear. Relatively more
minor is the potential for osteoporosis and metabolic complications,
such as diabetes and hyperlipidaemia. Hepatitis B disease has a sizabl
e risk of recurrence, but the most recent prophylaxis regimes have imp
roved relapse rates. Having survived the physical problems following t
ransplantation, most of which occur in the first 6 months, there are c
onsiderable psychosocial adjustments to be made particularly in the ca
se of children where growth and development may have been delayed. Des
pite all these difficulties, liver transplantation is an expanding and
optimistic area with enormous potential.